MorphoSys (MOR)

Business description

MorphoSys is a German biotechnology company that uses its proprietary antibody platforms to produce human antibodies for therapeutic use across a range of indications for partners and to develop its own pipeline.

Stock data

Market cap.€1204.8m
Last close€45.40
High / Low (52 weeks)€76.2 / €35.2
Stock market listingDE
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual7.66.9(31.2)
Relative *2.7(0.2)(21.3)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Achillion Pharmaceuticals Acorda Therapeutics
Actinium Pharmaceuticals Active Biotech
Acucela Addex Therapeutics
Adherium Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
AFT Pharmaceuticals Agennix
Akari Therapeutics Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
Astex Pharmaceuticals Athersys
Atossa Genetics Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
Bone Therapeutics BrainStorm Cell Therapeutics
BTG C4X Discovery Holdings
Can-Fite BioPharma Capstone Therapeutics
Carmat Cell Therapy
Celldex Therapeutics Cellectis
Celyad Cerulean Pharma
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel co.don AG
Consort Medical Crossject
Crossject SA Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics Egalet Corporation
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Epistem Holdings Erytech Pharma
Esperion Therapeutics Evolva
Evotec Exact Sciences
Exelixis Formycon
Forward Pharma Futura Medical
Galapagos Galmed Pharmaceuticals
Genfit Genmab
Genticel GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings ImmuPharma
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
International Stem Cell Corporation Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Lifewatch AG Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene Midatech Pharma
Molecular Partners MolMed
Mologen AG Momenta Pharmaceuticals
Nanobiotix Nanosonics
Nektar Therapeutics NeoStem
Neovacs Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novogen NPS Pharmaceuticals
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Oryzon Genomics
Ossur OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Prescient Therapeutics
Prima BioMed Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences QRxPharma
Quantum Pharmaceuticals Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
RXi Pharmaceuticals Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals TearLab Corp
Tekmira TESARO
Theraclion Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Group Tissue Therapies
Titan Pharmaceuticals Tonix Pharmaceuticals
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
TruScreen Ltd TxCell SA
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma PLC
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Wilex
Xencor Zafgen
Zealand Pharma Ziopharm Oncology

Company news

MorphoSys AG : MorphoSys Provides Update on Results From Partner's Phase 2b/3 ...

Thu, 21 Apr 2016 06:00:00 GMT

MorphoSys AG: Announcement of the Convening of the AGM in Munich/Germany on ...

Wed, 20 Apr 2016 13:21:28 GMT

MorphoSys AG : MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration

Thu, 26 Mar 2015 16:23:10 GMT

MorphoSys AG : MorphoSys to Receive Milestone Payment for Guselkumab Program ...

Mon, 13 Apr 2015 05:36:15 GMT

MorphoSys Announces Share Buy-Back Program

Wed, 24 Feb 2016 16:03:07 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2014A 64.0 (1.8) (1.6) (1.3) N/A N/A
2015A 106.2 21.4 22.1 62.8 72.3 N/A
2016E N/A N/A N/A N/A N/A N/A
2017E N/A N/A N/A N/A N/A N/A

Last updated on 30/03/2016

Investment summary

MorphoSys has a broad portfolio with 103 total programmes, 14 of those proprietary, including programmes for MOR208, MOR202 and MOR209. MOR208 is an Fc-enhanced antibody targeting CD19. MorphoSys will begin two Phase II trials of MOR208 in DLBCL and CLL soon, with a pivotal study in DLBCL planned for 2017. MOR202 is an anti-CD38 antibody in Phase I/IIa for multiple myeloma. A Phase I/IIa study of MOR202 in combination with dexamethasone in relapsed or refractory multiple myeloma patients is nearing completion. MOR209, an anti-PSMA/CD3 antibody, is in Phase I trials for prostate cancer. Among the partnered programmes, J&J has now initiated five Phase III studies with guselkumab in psoriasis, a programme with blockbuster potential.

Last updated on 31/03/2016

Industry outlook

The pharmaceutical industry is out-licensing more drug discovery and developing more biological products, both trends that should benefit MorphoSys. Also, there is increasing demand for novel therapies, such as those in MorphoSys's proprietary pipeline.

Last updated on 31/03/2016

Key management

Jens Holstein, CFO

Company address

Lena-Christ-Str. 48
82152 Martinsried/Planegg
Germany
+49 (0)89 / 899 27-0
View website